Inari Medical Inc

Análisis de la acción Inari Medical Inc (NARI)

$79.970

+0.040 (+0.05%)Al cierre

Loading chart…
Máximo
79.990
Apertura
79.970
Precio medio ponderado por volumen
79.97
Volumen
2.36M
Capitalización
2.73B
Mínimo
79.960
Importe
188.66M
EV/EBITDA, TTM
243.88

Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.

Métricas de valoración

El PER previsto actual de Inari Medical Inc (NARI) es 305.46, frente a su media de 5 años de 6.05.

PER previsto

Valor razonable
Media 5A P/E
6.05
P/E actual
305.46
Sobrevalorada
460.93
Infravalorada
-448.82

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
356.73
EV/EBITDA actual
243.88
Sobrevalorada
1726.33
Infravalorada
-1012.88

Precio/ventas previsto

Valor razonable
Media 5A P/S
7.35
P/S actual
6.60
Sobrevalorada
10.08
Infravalorada
4.63

Cronología de eventos

2025-02-19 (ET)

08:33:55

Stryker completes acquisition of Inari Medical

04:55:00

Kadant to replace Inari Medical in S&P 600 at open on 2/19

2025-02-13 (ET)

16:18:54

Kadant to replace Inari Medical in S&P 600 at open on 2/19

2025-01-17 (ET)

15:21:43

Stryker commences $80 per share cash offer for Inari Medical

2025-01-06 (ET)

15:09:39

Stryker to acquire Inari Medical for $80 per share in cash

Noticias

Preguntas frecuentes sobre NARI, respondidas por Alphio AI

Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar